February 14, 2018 — The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone…Original Article
FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer
